



31 October 2023

## **Hemogenyx Pharmaceuticals plc**

("Hemogenyx Pharmaceuticals" or the "Company")

### **Total Voting Rights**

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 October 2023 consists of 1,153,065,988 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,153,065,988.

The figure of 1,153,065,988 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

### **Enquiries:**

#### **Hemogenyx Pharmaceuticals plc**

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Peter Redmond, Director

<https://hemogenyx.com>

[headquarters@hemogenyx.com](mailto:headquarters@hemogenyx.com)

[peter.redmond@hemogenyx.com](mailto:peter.redmond@hemogenyx.com)

#### **SP Angel Corporate Finance LLP**

Matthew Johnson, Vadim Alexandre, Adam Cowl

Tel: +44 (0)20 3470 0470

#### **Peterhouse Capital Limited**

Lucy Williams, Duncan Vasey, Charles Goodfellow

Tel: +44 (0)20 7469 0930